David Rodman

David Rodman

Director Técnico/Científico/I+D en MINERALYS THERAPEUTICS, INC. .

Fortuna: 2 M $ al 31/05/2026

71 años
Health Technology
Consumer Services
Commercial Services

Perfil

David M.
Rodman
is currently a Member-Editorial Board at American Thoracic Society, Inc. and Chief Medical Officer at Mineralys Therapeutics, Inc. since 2021.
Former roles include Vice President-Clinical Development at Vertex Pharmaceuticals, Inc. from 2011 to 2014; Executive Vice President-Research & Development at miRagen Therapeutics, Inc.; Professor at The University of Colorado; Head-Respiratory Translational Medicine at Novartis Institutes for Biomedical Research, Inc.; Chief Medical Officer & Executive VP-Discovery at Nivalis Therapeutics, Inc. from 2016 to 2017; and Executive Vice President-Research & Development at ProQR Therapeutics NV.
Education includes a doctorate from the University of Pennsylvania in 1980 and an undergraduate degree from Haverford College in 1976.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
17/06/2026 57.095 ( 0,08 % ) 2 M $ 31/05/2026

Cargos activos de David Rodman

EmpresasCargoInicio
MINERALYS THERAPEUTICS, INC. Director Técnico/Científico/I+D 01/01/2021
Corporate Officer/Principal -

Antiguos cargos conocidos de David Rodman.

EmpresasCargoFin
Director Técnico/Científico/I+D 15/01/2017
VERTEX PHARMACEUTICALS INCORPORATED Director Técnico/Científico/I+D 01/04/2014
PROQR THERAPEUTICS N.V. Director Técnico/Científico/I+D -
Corporate Officer/Principal -
Corporate Officer/Principal -
Ver el detalle de la experiencia de David Rodman.

Formación de David Rodman.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

85

Relaciones de 1er grado

10

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas10

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN